Search Results - "Farley, Joel"

Potential benefits of incorporating social determinants of health screening on comprehensive medication management effectiveness by Farley, Joel F, Pradeep, Swetha

“…Increasingly, pharmacists are asked to incorporate social determinants of health (SDoH) identification and referral into clinical practice. However, to date,…”
Get full text

Utilization and impact of SLGT2 inhibitors among diabetes patients in a nationally representative survey: Findings from NHANES 2013–2020 by Shen, Tsung-Hua, Farley, Joel F.

“…The purpose of this study is to examine patterns of utilization for antidiabetic medications among a nationally representative sample of the US population…”
Get full text

Are the Benefits of Value-Based Insurance Design Conclusive? by Farley, Joel F

“…Questions about the clinical significance of improvements to medication adherence resulting from value-based insurance design (VBID) policies persist in the…”
Get full text

Providers' mediating role for medication adherence among cancer survivors by Trogdon, Justin G, Amin, Krutika, Gupta, Parul, Urick, Benjamin Y, Reeder-Hayes, Katherine E, Farley, Joel F, Wheeler, Stephanie B, Spees, Lisa, Lund, Jennifer L

“…We conducted a mediation analysis of the provider team's role in changes to chronic condition medication adherence among cancer survivors. We used a…”
Get full text

Prevalence and patterns of catastrophic spending for antidiabetic medication in 2020 by Devine, Joshua W., Lim, Dooyoung, Lugo, Amy, Farley, Joel F.

“…The cost of drugs to treat diabetes in the United States is high. In this study, we looked at data from a large survey in the United States to see how much…”
Get full text

Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease by Shen, Tsung‐Hua, Aby, Elizabeth S., Vock, David, Farley, Joel F.

“…Aim To compare the effectiveness of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) with dipeptidyl peptidase‐4 inhibitors (DPP4is) on major liver…”
Get full text

Copayment reductions generate greater medication adherence in targeted patients by Maciejewski, Matthew L, Farley, Joel F, Parker, John, Wansink, Daryl

“…A large value-based insurance design program offered by Blue Cross Blue Shield of North Carolina eliminated generic medication copayments and reduced…”
Get full text

Factors Driving Anticoagulant Selection in Patients With Atrial Fibrillation in the United States by Lauffenburger, Julie C., PharmD, PhD, Farley, Joel F., PhD, Gehi, Anil K., MD, Rhoney, Denise H., PharmD, Brookhart, M. Alan, PhD, Fang, Gang, PharmD, MS, PhD

“…With the introduction of novel oral anticoagulants (NOACs), the factors driving anticoagulant selection in atrial fibrillation (AF) in real-world practice are…”
Get full text

Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma by Murugappan, Meena N., King-Kallimanis, Bellinda L., Bhatnagar, Vishal, Kanapuru, Bindu, Farley, Joel F., Seifert, Randall D., Stenehjem, David D., Chen, Ting-Yu, Horodniceanu, Erica G., Kluetz, Paul G.

“…Purpose The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items…”
Get full text

Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy by Dauner, Daniel G, Farley, Joel F

“…: The SUSTAIN-6 trial showed significantly higher rates of retinopathy complications in the semaglutide group compared to placebo. Observational studies have…”
Get more information

Do enhanced services pharmacies serve sicker patients? by Urick, Benjamin Y., Farley, Joel F.

“…The objective of this study was to evaluate the relationship between patients’ demographics, health status, and health resource use and attribution to a…”
Get full text

Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study by Lauffenburger, Julie C, Farley, Joel F, Gehi, Anil K, Rhoney, Denise H, Brookhart, M Alan, Fang, Gang

“…The recent availability of dabigatran, a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond…”
Get full text

Is it time to replace the star ratings adherence measures? by Farley, Joel F, Urick, Benjamin Y

“…Measures of medication adherence to noninsulin diabetes medications (NIDM), statins, and renin angiotensin system antagonists (RASA) have been continuously…”
Get full text

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention by Kumar, Arun, Lutsey, Pamela L., St. Peter, Wendy L., Schommer, Jon C., Van't Hof, Jeremy R., Rajpurohit, Abhijeet, Farley, Joel F.

“…In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared with…”
Get full text

Patient Medication Adherence Among Pharmacies Participating in a North Carolina Enhanced Services Network by Urick, Benjamin Y, Bhosle, Monali, Farley, Joel F

“…Improving medication adherence can reduce health care spending, and studies have demonstrated community pharmacists can positively affect adherence through the…”
Get full text

Impact of STEADI‐Rx: A Community Pharmacy‐Based Fall Prevention Intervention by Blalock, Susan J., Ferreri, Stefanie P., Renfro, Chelsea P., Robinson, Jessica M., Farley, Joel F., Ray, Neepa, Busby‐Whitehead, Jan

“…OBJECTIVES To evaluate the effects of a community pharmacy‐based fall prevention intervention (STEADI‐Rx) on the risk of falling and use of medications…”
Get full text

The Association Between Medicare Low-Income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer by Chou, Yi-Ting, Farley, Joel F, Stinchcombe, Thomas E, Proctor, Amber E, Lafata, Jennifer Elston, Dusetzina, Stacie B

“…Abstract Background High out-of-pocket costs may impact anticancer treatment uptake. The Low-Income Subsidy (LIS) program can reduce patient out-of-pocket cost…”
Get full text

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study by Kumar, Arun, Lutsey, Pamela L., St Peter, Wendy L., Schommer, Jon C., Van't Hof, Jeremy R., Rajpurohit, Abhijeet, Farley, Joel F.

“…Comparative effectiveness evaluation of newer P2Y12 inhibitors (prasugrel and ticagrelor) compared with clopidogrel after acute coronary syndrome (ACS) is…”
Get full text

Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system by Dauner, Daniel G, Zhang, Rui, Adam, Terrence J, Leal, Eleazar, Heitlage, Viviene, Farley, Joel F

“…Many signal detection algorithms give the same weight to information from all products and patients, which may result in signals being masked or false…”
Get more information

Direct-acting antiviral retreatment patterns for hepatitis C by Hasan, Shaquib Al, Dauner, Daniel G, Rajpurohit, Abhijeet, Farley, Joel F

“…Despite the strong efficacy of direct-acting antivirals (DAAs) against the hepatitis C virus, many patients require a second regimen of DAA treatment. However,…”
Get full text